XORTX Therapeutics Inc. filings document foreign issuer reports for a clinical-stage pharmaceutical company developing therapies for gout and progressive kidney disease. The records describe its XRx-026, XRx-008, XRx-101, XRx-225 and VB4-P5 programs, including disease focus, development stage and acquired intellectual property, regulatory documentation and manufacturing data for the VB4-P5 kidney anti-fibrotic asset.
The company’s Form 6-K disclosures also cover capital structure and exchange-listing matters, including a completed share consolidation, Nasdaq continued-listing compliance, preliminary stockholders’ equity information, acquisition consideration involving common shares and pre-funded warrants, and shareholder meeting results. Governance filings report director elections, auditor appointments, stock option plan approval and related voting outcomes.
XORTX Therapeutics Inc. launched a registered direct offering to an institutional accredited investor, registering 572,470 common shares at $0.63 each, 1,177,530 pre-funded warrants at $0.62999 each with a $0.00001 exercise price, and 1,177,530 common shares underlying those warrants. The pre-funded warrants are immediately exercisable.
The fee table shows an aggregate offering price of $1,102,488, placement agent fees of $77,175, and proceeds before expenses of $1,025,313. The company estimates net proceeds of approximately $0.8 million for working capital and general corporate purposes. A beneficial ownership cap limits exercises above 4.99% (or, at the purchaser’s election at closing, 9.99%).
XRTX trades on the TSXV and Nasdaq. The company has applied to list the Shares and the Pre-Funded Warrant Shares on the TSXV and notified Nasdaq; TSXV approval is required. D. Boral Capital LLC is acting as exclusive placement agent on a best efforts basis. Delivery is expected on or about October 23, 2025, subject to customary conditions and TSXV approvals.